Wednesday, July 8, 2026

pharma · Menopause · Vulvovaginal Atrophy · TXMD

TherapeuticsMD

TherapeuticsMD is a pharma organization headquartered in Boca Raton, USA. It trades on NYSE under ticker TXMD. Primary therapeutic focus areas include Menopause, Vulvovaginal Atrophy, Secondary Amenorrhea, Contraception,

Boca Raton, USA HQ
53 Employees
Public company Type
TXMD · NYSE Ticker
Company details
Status
Public
HQ
Boca Raton, USA
Employees
53
Programs
6
Drugs
6
Patents
0
Clinical program

Progesterone

Phase 3 · small molecule · Secondary Amenorrhea

Progesterone for Secondary Amenorrhea is a Phase 3 program (small_molecule) at TherapeuticsMD with 1 ClinicalTrials.gov record(s).

← All TherapeuticsMD projects Phase 3 small molecule terminated

Internal code TXP13-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
TherapeuticsMD
Phase
Phase 3
Modality
small_molecule
Indication
Secondary Amenorrhea
Status
terminated
Trials
1